Zosano Pharma Corporation (NASDAQ:ZSAN) [Trend Analysis] moved down reacts as active mover, shares a loss -2.44% to traded at $1.20 and the percentage gap between open changing to regular change was 0.81%. ZosanaPharma Corp. presented positive trial results of its migraine treatment. Volume spiked to 12.4 million shares, compared with the full-day average of about 268,000 shares.
Zosana said a trial of its lead candidate, M207, which is a patch used to treatment migraine pain, achieved both co-primary endpoints of pain freedom and most-bothersome-symptom freedom in a phase 3 trial. The company said there were no serious adverse events in the trial. The firm’s current ratio calculated as 2.40 for the most recent quarter. As far as the returns are concern, the return on equity was recorded as -170.30% and return on investment was -64.10% while its return on asset stayed at -82.80%. The firm has total debt to equity ratio measured as 1.17.
Allergan plc (NYSE:AGN) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.28% to close at $246.36 with the total traded volume of 3.08 Million shares. Allergan plc (AGN) and ZELTIQ Aesthetics, Inc. (ZLTQ) reported that a definitive contract under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion. Allergan said the acquisition is immediately accretive and enhances global medical aesthetics portfolio with the addition of ZELTIQ’s CoolSculpting System.
The company currently anticipates closing the transaction in the second half of 2017. The CoolSculpting System is FDA-cleared to affect appearance through lipolysis or reduction of unwanted fat using a patented cooling technology. CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue.
“By adding the best-in-class body contouring CoolSculpting System to our best-in-class facial aesthetics, plastic surgery and regenerative medicine offerings we are creating a world-class aesthetics business,” said Brent Saunders, CEO of Allergan. The firm has institutional ownership of 87.30%, while insider ownership included 0.10%. Its price to sales ratio ended at 6.49. AGN attains analyst recommendation of 2.00 with week’s performance of 6.71%.